Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
|Articles|February 19, 2016
Translational Medicine: A “Team Sport”?
Author(s)DIA
February 19, 2016
Advertisement
Dr. Makoto Suematsu, President of the Japan Agency for Medical Research & Development (AMED); and Dr. Christopher P. Austin, Director of the National Center for Advancing Translational Sciences (NCATS), US National Institutes of Health; discuss how collaboration between their agencies will ultimately deliver better therapies more quickly to more patients.
Advertisement
Related to this article
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
As leaders, we must evaluate solutions to fragmentation by asking
the right questions.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5